NCT00742963 - Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma | Biotech Hunter

Enrollment

107

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

July 31, 2013

Study Completion Date

October 31, 2013

Conditions

Soft Tissue Sarcoma

Interventions

DRUG

TH-302

"TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.~Dose escalation dose levels:~Dose level -1 (if needed): 180 mg/m2 Starting dose: 240 mg/m2"

Trial Locations (9)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

46204

Indiana University Cancer Center, Indianapolis

55905

Mayo Clinic Rochester, Rochester

63110

Washingon University Siteman Cancer Center, St Louis

75201

Mary Crowley Cancer Research Centers, Dallas

85719

Arizona Cancer Center, Tucson

90403

Sarcoma Oncology Center, Santa Monica

94305

Stanford University, Stanford

02115

Dana Farber Cancer Institute, Boston